Halozyme Therapeutics (HALO) Debt Ratio (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Debt Ratio data on file, last reported at 0.8 in Q1 2026.

• On a quarterly basis, Debt Ratio rose 16.92% year-over-year to 0.8 in Q1 2026; TTM through Mar 2026 was 0.8, a 16.92% increase from a year earlier, with the FY2025 full-year figure at 0.85, up 16.27% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.8, down from 0.85 in the prior quarter.
• Over the last five years, Debt Ratio for HALO reached as high as 0.88 in Q1 2023 and fell as low as 0.68 in Q3 2025.
• Historically, Debt Ratio has averaged 0.78 across 5 years, with a median of 0.79 in 2023.
• Across the five-year window, Debt Ratio fell 17.96% in 2022 and climbed 18.12% in 2023, its largest moves.
• Year by year, Debt Ratio stood at 0.83 in 2022, then gained by 4.83% to 0.86 in 2023, then dropped by 15.64% to 0.73 in 2024, then advanced by 16.27% to 0.85 in 2025, then slipped by 5.43% to 0.8 in 2026.
• Per Business Quant data, the three most recent Debt Ratio figures were 0.8 in Q1 2026, 0.85 in Q4 2025, and 0.68 in Q3 2025.